Intellectual disability - microarray and sequencing
Gene: MAPK10 Amber List (moderate evidence)Following discussion with the clinical team, this gene has been demoted from Amber to Red, in accordance with the external review by Zornitza StarkCreated: 17 Aug 2020, 10:09 a.m. | Last Modified: 17 Aug 2020, 10:09 a.m.
Panel Version: 3.253
Red List (low evidence)
Only evidence comes from translocation cases reported in 2006 and 2013. Cannot find reports of SNVs. No P/LP variants reported in ClinVar. Rated Red on other panels as far as I can see.Created: 7 Mar 2020, 5:14 a.m. | Last Modified: 7 Mar 2020, 5:14 a.m.
Panel Version: 3.3
Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Phenotypes
Intellectual disability; seizures
Publications
Comment when marking as ready: Small amount of evidence for variants in this gene with an isolated ID presentation. Watchlist tag added.Created: 8 Mar 2018, 3:24 p.m.
I don't know
added watchlist tagCreated: 8 Mar 2018, 3:21 p.m.
Comment on list classification: Changed from Red to Amber after clinical review commentsCreated: 8 Mar 2018, 3:21 p.m.
After clinical review it was thought this gene should rated Amber. HB commented that PMID 23329067 details two cases with translocations where the breakpoints include MAPK10. One presented with ID in the absence of seizures, although cannot find wider support for this hypothesis. Worth marking as amber and watchlist on the ID panel.Created: 8 Mar 2018, 3:20 p.m.
Lennox-Gastaut syndrome (LGS) belongs to the group of severe childhood epileptic encephalopathies and is a severe form of epilepsy associated with intractable seizures and impaired cognition. Although there is enough evidence to support the phenotype, MAPK10 is a candidate gene tested for this disorder and variants within this gene are reported as part of current diagnostic practice.Created: 7 Mar 2018, 11:09 a.m.
Comment on phenotypes: added phenotype from Orphanet and Gene2PhenotypeCreated: 7 Mar 2018, 11:07 a.m.
Monoallelic confirmed on G2P, not on the imprinted gene list. This is a possible DD gene in Gene2Phenotype for EPILEPTIC ENCEPHALOPATHY LENNOX-GASTAUT TYPECreated: 7 Mar 2018, 11 a.m.
I am not sure if this should be a Green on the Intellectual Disability panel since it epilepsy associated with intractable seizures that result in the mental deterioration, ID is not independently present? It is currently rated Green on the Epilepsy Plus and Epileptic encephalopathy panels. To be reviewed by internal clinical team as to wether this gene should be Green on ID panel.Created: 7 Mar 2018, 10:57 a.m.
Red List (low evidence)
Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Phenotypes
EPILEPTIC ENCEPHALOPATHY LENNOX-GASTAUT TYPE (EELG)
Publications
Red List (low evidence)
Source: Expert Review Red was removed from gene: MAPK10
12.03.2018: Due to major updates completed (Phase 1, 2 and 3), this panel was promoted to Version 2 in order to reflect the major updates since November 2017 which have resulted in reviews for 836 genes added by Genomics England Curators and the Clinical Team, 130 new Green genes added to the interpretation pipeline (from 751 to 881 Green genes), and the gene total has increased from 1879 to 1927.
Expert Review Amber was added to MAPK10. Panel: Intellectual disability Model of inheritance for gene MAPK10 was set to MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown Publications for gene MAPK10 was set to ['23329067']
The Gel status was updated for this whole panel
The Gel status was updated for this whole panel
MAPK10 was created by ellenmcdonagh
MAPK10 was added to Intellectual disabilitypanel. Sources: Expert Review Red
If promoting or demoting a gene, please provide comments to justify a decision to move it.
Genes included in a Genomics England gene panel for a rare disease category (green list) should fit the criteria A-E outlined below.
These guidelines were developed as a combination of the ClinGen DEFINITIVE evidence for a causal role of the gene in the disease(a), and the Developmental Disorder Genotype-Phenotype (DDG2P) CONFIRMED DD Gene evidence level(b) (please see the original references provided below for full details). These help provide a guideline for expert reviewers when assessing whether a gene should be on the green or the red list of a panel.
A. There are plausible disease-causing mutations(i) within, affecting or encompassing an interpretable functional region(ii) of this gene identified in multiple (>3) unrelated cases/families with the phenotype(iii).
OR
B. There are plausible disease-causing mutations(i) within, affecting or encompassing cis-regulatory elements convincingly affecting the expression of a single gene identified in multiple (>3) unrelated cases/families with the phenotype(iii).
OR
C. As definitions A or B but in 2 or 3 unrelated cases/families with the phenotype, with the addition of convincing bioinformatic or functional evidence of causation e.g. known inborn error of metabolism with mutation in orthologous gene which is known to have the relevant deficient enzymatic activity in other species; existence of an animal model which recapitulates the human phenotype.
AND
D. Evidence indicates that disease-causing mutations follow a Mendelian pattern of causation appropriate for reporting in a diagnostic setting(iv).
AND
E. No convincing evidence exists or has emerged that contradicts the role of the gene in the specified phenotype.
(i)Plausible disease-causing mutations: Recurrent de novo mutations convincingly affecting gene function. Rare, fully-penetrant mutations - relevant genotype never, or very rarely, seen in controls. (ii) Interpretable functional region: ORF in protein coding genes miRNA stem or loop. (iii) Phenotype: the rare disease category, as described in the eligibility statement. (iv) Intermediate penetrance genes should not be included.
It’s assumed that loss-of-function variants in this gene can cause the disease/phenotype unless an exception to this rule is known. We would like to collect information regarding exceptions. An example exception is the PCSK9 gene, where loss-of-function variants are not relevant for a hypercholesterolemia phenotype as they are associated with increased LDL-cholesterol uptake via LDLR (PMID: 25911073).
If a curated set of known-pathogenic variants is available for this gene-phenotype, please contact us at [email protected]
We classify loss-of-function variants as those with the following Sequence Ontology (SO) terms:
Term descriptions can be found on the PanelApp homepage and Ensembl.
If you are submitting this evaluation on behalf of a clinical laboratory please indicate whether you report variants in this gene as part of your current diagnostic practice by checking the box
Standardised terms were used to represent the gene-disease mode of inheritance, and were mapped to commonly used terms from the different sources. Below each of the terms is described, along with the equivalent commonly-used terms.
A variant on one allele of this gene can cause the disease, and imprinting has not been implicated.
A variant on the paternally-inherited allele of this gene can cause the disease, if the alternate allele is imprinted (function muted).
A variant on the maternally-inherited allele of this gene can cause the disease, if the alternate allele is imprinted (function muted).
A variant on one allele of this gene can cause the disease. This is the default used for autosomal dominant mode of inheritance where no knowledge of the imprinting status of the gene required to cause the disease is known. Mapped to the following commonly used terms from different sources: autosomal dominant, dominant, AD, DOMINANT.
A variant on both alleles of this gene is required to cause the disease. Mapped to the following commonly used terms from different sources: autosomal recessive, recessive, AR, RECESSIVE.
The disease can be caused by a variant on one or both alleles of this gene. Mapped to the following commonly used terms from different sources: autosomal recessive or autosomal dominant, recessive or dominant, AR/AD, AD/AR, DOMINANT/RECESSIVE, RECESSIVE/DOMINANT.
A variant on one allele of this gene can cause the disease, however a variant on both alleles of this gene can result in a more severe form of the disease/phenotype.
A variant in this gene can cause the disease in males as they have one X-chromosome allele, whereas a variant on both X-chromosome alleles is required to cause the disease in females. Mapped to the following commonly used term from different sources: X-linked recessive.
A variant in this gene can cause the disease in males as they have one X-chromosome allele. A variant on one allele of this gene may also cause the disease in females, though the disease/phenotype may be less severe and may have a later-onset than is seen in males. X-linked inactivation and mosaicism in different tissues complicate whether a female presents with the disease, and can change over their lifetime. This term is the default setting used for X-linked genes, where it is not known definitately whether females require a variant on each allele of this gene in order to be affected. Mapped to the following commonly used terms from different sources: X-linked dominant, x-linked, X-LINKED, X-linked.
The gene is in the mitochondrial genome and variants within this can cause this disease, maternally inherited. Mapped to the following commonly used term from different sources: Mitochondrial.
Mapped to the following commonly used terms from different sources: Unknown, NA, information not provided.
For example, if the mode of inheritance is digenic, please indicate this in the comments and which other gene is involved.